Treatment Selection in a Patient with Decompensated CirrhosisPremiere Date: Monday, May 16, 2022
This activity offers CE credit for:%>
- ABIM (MOC)
- Medicine (accme)
- Nursing (ANCC)
- Pharmacy (acpe)
- PA (aapa)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Tuesday, May 16, 2023
Note: Credit Is No Longer Available
|Nancy Reau, MD (Moderator)
Professor of Medicine
Richard B. Capps Chair of Hepatology
Chief, Section of Hepatology
Associate Director, Solid Organ Transplantation
Rush University Medical Center
|Paul Y. Kwo, MD
Professor of Medicine
Director of Hepatology
Stanford University School of Medicine
|Joseph K. Lim, MD (Reviewer/Advisor)
Professor of Medicine
Director, Clinical Hepatology
Vice-Chief, Section of Digestive Diseases
Yale University School of Medicine
New Haven, CT
Chronic hepatitis C virus (HCV) infection is associated with a 15- to 20-fold greater risk of hepatocellular carcinoma (HCC) compared to those without HCV. Individuals with HCV-related cirrhosis are at risk for HCC development, underscoring the importance of routine HCC surveillance in patients with HCV. Therefore, as a crucial component of HCV management, clinicians should integrate routine surveillance for HCC in patients with HCV, as recommended in current guidelines. Evidence shows that clinicians have misconceptions regarding appropriate tests to detect HCC and need to engage more in following HCC surveillance guidelines regarding screening intervals and imaging modality. To increase surveillance rates, it is crucial that all HCPs managing patients with HCV understand how to implement the most recent guidelines in practice.
This CMEO BriefCase will introduce a case involving the incorporation of routine surveillance for HCC in a patient with HCV. Join our faculty experts as they delve into the epidemiology and shared pathobiology of HCV and decompensated cirrhosis, identify compensated versus decompensated cirrhosis, and discuss surveillance strategies for HCC.
At the end of this CE activity, participants should be able to:
- Integrate routine surveillance for HCC into clinical follow-up for patients with HCV.
Supported by an educational grant from Gilead Sciences, Inc.
U.S. and international physicians, PAs, nurse practitioners, nurses, and pharmacists specializing in primary care
Through a mutual recognition agreement between the AMA and the UEMS-EACCME, European physicians completing an e-learning activity from a US-based ACCME-accredited CME provider can use AMA PRA Category 1 Credit™ toward their credit requirements. CME Outfitters is based in Radnor, Pennsylvania, USA. Please retain your certificate as proof of completion.
ABIM MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Royal College MOC:
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
MIPS Improvement Activity:
This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Reau reports the following financial relationships:
Consultant: AbbVie Inc.; Gilead Sciences, Inc.; Intercept Pharmaceuticals, Inc.; and Merck & Co., Inc.
Grants/Research Support: GENFIT; Intercept Pharmaceuticals, Inc.; and Shire
Dr. Kwo reports the following financial relationships:
Advisory Board: AbbVie Inc.; Aligos Therapeutics Inc.; Ambys Medicines; Antios Therapeutics, Inc.; CVS; Eisai Inc.; Enanta Pharmaceuticals, Inc.; Gilead Sciences, Inc.; HepQuant; Mallinckrodt Pharmaceuticals; and Surrozen
Consultant: Drug Farm; Durect Corporation; Generon; Inventiva; Mirum Pharmaceuticals; and Syneos Health
Grants: Altimmune; Arrowhead Pharmaceuticals, Inc.; Assembly Biosciences, Inc.; Bristol Myers Squibb; Eiger BioPharmaceuticals; Novo Nordisk; Target RWE Registries; and Ultragenyx Pharmaceutical
Stock (Directly Purchased): Durect Corporation
Dr. Lim (Reviewer/Advisor) reports the following financial relationships:
Research Support: Allergan; Celgene Corporation; Eiger BioPharmaceuticals, Inc.; GENFIT; Gilead Sciences, Inc.; Pfizer Inc.; and Viking Therapeutics
The following peer reviewer and CME Outfitters staff have no financial relationships to disclose:
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).